Overview
MABPHARM-B (2181)
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoi...
- Open
- 0.490
- High
- 0.490
- Low
- 0.490
- Prev. Close
- 0.490
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- -14.29%
- Amplitude
- 0.00%
- 52wk High
- 0.810
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 0.310
- HK Mkt Cap
- 2.02B
- Market CapHKD
- 2.02B
- P/ETTM
- 20.51
- P/EDynamic
- 27.98
- P/EStatic
- --
- EPSTTM
- 0.0239
- EPSDynamic
- 0.0175
- EPSStatic
- --
- BVPS
- 0.05
- P/B
- 9.05
- HK Shares
- 4.12B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 4.12B
- Min lot size
- 2,000
- Currency
- HKD
MABPHARM-B Analyst Rating
View moreForecast & Rating
Jul 28, 2022- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Mabpharm staged a rebound from intraday lows, recovering from 0.365 HKD to close at 0.395 HKD in the afternoon session, down 5.95% from the previous close of 0.420 HKD. The turnaround was driven by the company's full-year net profit of 57.13 million RMB, marking a return to profitability, which attracted buying interest near the 52-week low. Despite the stock trading 55.11% below its 52-week high of 0.88 HKD and down 21% YTD, Q4 revenue surged 159.61% YoY to 207 million HKD, with net profit up 286.62% YoY, reflecting fundamental improvement. However, the stock remains below both its MA20 (0.402 HKD) and MA60 (0.437 HKD), suggesting lingering technical headwinds.
News
Market Movers · MABPHARM-B rose approximately 16%
Market Movers · MABPHARM-B fell approximately 10%
Market Movers · MABPHARM-B fell approximately 9%
Market Movers · Mabpharm soars 22% in Hong Kong trading
Market Movers · MABPHARM-B fell approximately 7%
Global Report · Biotech Breakthroughs vs Governance Scandals: Hong Kong's Niche Stock Divide
